Skip to main content
. Author manuscript; available in PMC: 2018 Aug 29.
Published in final edited form as: Am J Transplant. 2015 Aug 28;16(1):213–220. doi: 10.1111/ajt.13434

Table 2.

Transplant and Immunologic Characteristics

C4d-Negative
AMR (n=51)
C4d-Positive
AMR (n=156)
P-value
Transplant Type 0.7
Live Donor
Compatible 2 (3.9%) 4 (2.6%)
HLA-Incompatible 34 (66.7%) 101 (64.7%)
ABO-Incompatiblea 1 (2.0%) 11 (7.0%)
Deceased Donor
Compatible 3 (5.9%) 11 (7.0%)
HLA-Incompatible 11 (21.6%) 29 (18.6%)
Prior Transplant 28 (54.9%) 88 (56.4%) 0.8
Median PRA (IQR) 93 (88–100) 96 (73–100) 0.9
Zero HLA Mismatch 0 (0.0%) 1 (0.6%) 0.6
Pre-Desensitization Antibody Strengthb 0.7
CDC+ 11 (24.4%) 39 (29.8%)
FCXM+ 23 (51.1%) 66 (50.4%)
Luminex+ 11 (24.4%) 26 (19.8%)
Induction 0.6
Thymoglobulin 26 (63.4%) 90 (63.8%)
Daclizumab 12 (29.3%) 46 (32.6%)
Basiliximab 3 (7.3%) 5 (3.5%)
HLA Antibody Classb 0.4
Class I 16 (33.3%) 41 (28.3%)
Class II 14 (29.2%) 33 (22.8%)
Class I and II 18 (37.5%) 71 (49.0%)
Median Number of Biopsiesc (IQR) 5 (2–6) 5 (4–7) 0.05
Clinical Presentation of AMRd 28 (54.9%) 133 (85.3%) <0.001
AMR Treated 16 (31.4%) 118 (75.6%) <0.001
Death-Censored Graft Loss 0.4
1 Year Post AMR-Defining Biopsy 93.4% (80.8–97.8%) 86.8% (80.1–91.4%)
2 Years Post AMR-Defining Biopsy 90.2% (75.7–96.3%) 82.6% (75.0–88.0%)
3 Years Post AMR-Defining Biopsy 90.2% (75.7–96.3%) 77.7% (69.3–84.0%)

AMR - antibody-mediated rejection, IQR - interquartile range, CDC+ - complement-dependent cytotoxic crossmatch, FCXM+ - flow cytometric crossmatch

a

ABO-incompatible recipients who also had anti-HLA DSA were studied as members of the incompatible live donor group.

b

Percentages are of those patients with anti-HLA DSA (live and deceased donor recipients).

c

Median number of biopsies performed for the duration of follow-up for the life of the allograft.

d

Clinical episodes of AMR were defined as those that had evidence of graft dysfunction, manifested as an increase in serum creatinine by ≥20% from baseline, treatment of cell-mediated rejection and/or thrombotic microangiopathy within the two prior weeks, the need for hemodialysis >7 days post-transplant, or new onset proteinuria at the time of the AMR-defining biopsy.